Overview

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

Status:
Completed
Trial end date:
2016-03-31
Target enrollment:
Participant gender:
Summary
This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
Details
Lead Sponsor:
Bayer
Treatments:
Sorafenib